Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Accured Expenses (2017 - 2025)

Sutro Biopharma's Change in Accured Expenses history spans 9 years, with the latest figure at -$6.8 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 451.67% year-over-year to -$6.8 million; the TTM value through Sep 2025 reached $5.2 million, down 74.73%, while the annual FY2024 figure was -$1.8 million, 107.04% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$6.8 million at Sutro Biopharma, down from $1.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $27.1 million in Q4 2023 and bottomed at -$7.6 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $1.4 million (2022), against an average of $1.9 million.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 1426.82% in 2021 before it tumbled 1181.54% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $5.2 million in 2021, then soared by 45.1% to $7.6 million in 2022, then surged by 256.27% to $27.1 million in 2023, then plummeted by 82.16% to $4.8 million in 2024, then plummeted by 240.17% to -$6.8 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Change in Accured Expenses are -$6.8 million (Q3 2025), $1.6 million (Q2 2025), and $5.6 million (Q1 2025).